Despite current antipsychotic treatment, the majority of people with schizophrenia continue
to exhibit persistent positive and negative symptoms and cognitive impairments. An
alternative approach to the use of psychotropic agents for the treatment of persistent
symptoms is the use of anti-inflammatory agents to reverse the pro-inflammatory state
hypothesized to underlie the symptom and sign manifestations of the illness.
The investigators primary hypothesis is that add-on anti-inflammatory combination therapy
will have significant beneficial effects on persistent positive symptoms and cognitive
impairments.
The investigators secondary hypotheses are:
1. add-on anti-inflammatory combination therapy will be associated with improvements in
depressive and negative symptoms and a reduction in pro-inflammatory cytokines
2. add-on anti-inflammatory combination therapy compared to placebo will not be associated
with elevated adverse risk.
Phase:
N/A
Details
Lead Sponsor:
University of Maryland University of Maryland, Baltimore